ABBV-383, a novel BCMA/CD3 bispecific antibody for the treatment of RRMM

Here, the Multiple Myeloma Hub presents data from an ongoing, open-label, phase I clinical trial investigating ABBV-383 in...

Quality of life in patients with multiple myeloma after CAR-T cell therapy

During the 19th International Myeloma Society Annual Meeting, Sidana discussed the QoL for patients with MM following CAR...

Ide-cel in RRMM: Real-world experience and biomarkers of response

During the 19th IMS Annual Meeting, Doris Hansen presented real-world data on patients with RRMM treated with ide-cel, which we...

Mezigdomide with bortezomib or carfilzomib for RRMM

At the 19th IMS Annual Meeting, Paul Richardson presented results from the CC-92480-MM-002 phase I/II dose escalation trial, where mezigdomide is...

RG2634, a novel bispecific antibody targeting GPRC5D, for the treatment of RRMM

GRPC5D, a G protein-coupled receptor, is a key therapeutic target in multiple myeloma (MM) as it is highly expressed on...

Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial

In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with...

Efficacy of OriCAR-017, a GPRC5D-directed CAR T-cell therapy, in patients with R/R MM: Findings from the POLARIS study

OriCAR-017 is a second-generation, autologous, GPRC5D-directed CAR T-cell...

Efficacy and safety of ARI0002h, an academic BCMA-directed CAR T-cell therapy for RRMM

ARI0002h is a 4-1BB based CAR T-cell product containing a humanized single chain variable BCMA-targeting...

CD43 as an adverse prognostic marker for MM and other hematologic malignancies

Here, the Multiple Myeloma Hub considers the work of Xueqin Ning and colleagues., we summarize the data from their...

Current perspectives on circulating tumor cells in newly diagnosed MM eligible for transplant

Here, we present promising data around the measurement of CTCs in the investigation and management of...

Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial

In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with...

Classification and treatment of frail and ultra frail patients with multiple myeloma: challenges and future perspectives

Here, we review an oral presentation, given on May 15, 2022, at the 8th World...